FGF19 and chronic kidney disease: After treatment with FGF19, the CKD mice displayed a marked reduction in their glucose excursion during ip-GTT (area under curve (AUC) 12,573 ± 456 vs. 16,693 ± 2465 mg/dl min−1, p < 0.0001, in FGF19-treated CKD mice vs CKD mice) (Fig. 4B, C).